{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:56:48Z","timestamp":1787065008471,"version":"build-2736575974"},"reference-count":212,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.semcancer.2020.03.011","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:44:12Z","timestamp":1589147052000},"page":"279-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Drug rechanneling: A novel paradigm for cancer treatment"],"prefix":"10.1016","volume":"68","author":[{"given":"Itishree","family":"Kaushik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharavan","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahdeo","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 8","key":"10.1016\/j.semcancer.2020.03.011_bib0010","doi-asserted-by":"crossref","first-page":"viii15","DOI":"10.1093\/annonc\/mdl983","article-title":"The rising burden of cancer in the developing world","volume":"17","author":"Kanavos","year":"2006","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.011_bib0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"28","key":"10.1016\/j.semcancer.2020.03.011_bib0040","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: justum pretium--the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0045","doi-asserted-by":"crossref","first-page":"212297","DOI":"10.7573\/dic.212297","article-title":"Evaluating cost benefits of combination therapies for advanced melanoma","volume":"5","author":"Jensen","year":"2016","journal-title":"Drugs Context"},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tips.2016.03.004","article-title":"Serendipity in Cancer drug discovery: rational or coincidence?","volume":"37","author":"Prasad","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.011_bib0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","article-title":"Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds","volume":"21","author":"Wurth","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0070","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/S0959-8049(17)30479-3","article-title":"Beyond aspirin and metformin: the untapped potential of drug repurposing in oncology","volume":"72","author":"Bouche","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology--patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7270","key":"10.1016\/j.semcancer.2020.03.011_bib0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2016.09.013","article-title":"Tertiary amine mediated targeted therapy against metastatic lung cancer","volume":"241","author":"Zhou","year":"2016","journal-title":"J. Control. Release"},{"issue":"3-4","key":"10.1016\/j.semcancer.2020.03.011_bib0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drudis.2012.08.005","article-title":"In silico drug repositioning: what we need to know","volume":"18","author":"Liu","year":"2013","journal-title":"Drug Discov. Today"},{"issue":"13","key":"10.1016\/j.semcancer.2020.03.011_bib0095","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1073\/pnas.1337088100","article-title":"Systematic discovery of multicomponent therapeutics","volume":"100","author":"Borisy","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.011_bib0100","doi-asserted-by":"crossref","first-page":"e101708","DOI":"10.1371\/journal.pone.0101708","article-title":"Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity","volume":"9","author":"Roix","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0105","first-page":"51","article-title":"Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer","volume":"58","author":"Matsuyama","year":"2017","journal-title":"Can. Vet. J."},{"issue":"7503","key":"10.1016\/j.semcancer.2020.03.011_bib0110","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"issue":"9759","key":"10.1016\/j.semcancer.2020.03.011_bib0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0120","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.011_bib0130","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.bjc.6603259","article-title":"Cancer risk among users of neuroleptic medication: a population-based cohort study","volume":"95","author":"Dalton","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"Suppl","key":"10.1016\/j.semcancer.2020.03.011_bib0135","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF00442551","article-title":"The history of clozapine","volume":"99","author":"Hippius","year":"1989","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0140","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fphar.2018.00218","article-title":"Drug repositioning in glioblastoma: a pathway perspective","volume":"9","author":"Tan","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"7772","key":"10.1016\/j.semcancer.2020.03.011_bib0145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(72)92955-8","article-title":"Chlorpromazines and cancer","volume":"2","author":"Csatary","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0150","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.schres.2017.08.065","article-title":"The incidence rate of cancer in patients with schizophrenia: a meta-analysis of cohort studies","volume":"195","author":"Li","year":"2018","journal-title":"Schizophr. Res."},{"issue":"2-3","key":"10.1016\/j.semcancer.2020.03.011_bib0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2011.02.018","article-title":"The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study","volume":"129","author":"Chou","year":"2011","journal-title":"Schizophr. Res."},{"issue":"2-3","key":"10.1016\/j.semcancer.2020.03.011_bib0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.schres.2004.06.016","article-title":"Cancer in schizophrenia: is the risk higher or lower?","volume":"73","author":"Grinshpoon","year":"2005","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib0165","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/cncr.21574","article-title":"Reduced cancer incidence among patients with schizophrenia","volume":"104","author":"Barak","year":"2005","journal-title":"Cancer"},{"issue":"2-3","key":"10.1016\/j.semcancer.2020.03.011_bib0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0920-9964(01)00308-5","article-title":"The association between schizophrenia and cancer: a population-based mortality study","volume":"57","author":"Cohen","year":"2002","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0175","first-page":"1952","article-title":"Inhibition of the growth of mouse melanoma by chlorpromazine","volume":"29","author":"Van Woert","year":"1969","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0180","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0447.1992.tb10325.x","article-title":"Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients","volume":"85","author":"Mortensen","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0185","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","article-title":"The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells","volume":"34","author":"Shin","year":"2013","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3858\/emm.2010.42.5.041","article-title":"Chlorpromazine activates p21Waf1\/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells","volume":"42","author":"Shin","year":"2010","journal-title":"Exp. Mol. Med."},{"issue":"23","key":"10.1016\/j.semcancer.2020.03.011_bib0195","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1158\/0008-5472.CAN-07-2235","article-title":"The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action","volume":"67","author":"Lee","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-003-0738-1","article-title":"Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes","volume":"53","author":"Zhelev","year":"2004","journal-title":"Phenothiazines and leukemia. Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/mutage\/ger067","article-title":"Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer","volume":"27","author":"Naccarati","year":"2012","journal-title":"Mutagenesis"},{"issue":"29","key":"10.1016\/j.semcancer.2020.03.011_bib0210","doi-asserted-by":"crossref","first-page":"27580","DOI":"10.18632\/oncotarget.4768","article-title":"Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0215","doi-asserted-by":"crossref","first-page":"e27186","DOI":"10.1371\/journal.pone.0027186","article-title":"Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"issue":"4238","key":"10.1016\/j.semcancer.2020.03.011_bib0220","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0225","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1017\/S1461145707008292","article-title":"Haloperidol regulates the phosphorylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex","volume":"11","author":"Kim","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/07853890600551037","article-title":"Targeting the ERK signaling pathway in cancer therapy","volume":"38","author":"Kohno","year":"2006","journal-title":"Ann. Med."},{"issue":"25-26","key":"10.1016\/j.semcancer.2020.03.011_bib0235","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lfs.2012.10.002","article-title":"Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells","volume":"91","author":"Kim","year":"2012","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)00045-6","article-title":"Pharmacology of drugs that alter multidrug resistance in cancer","volume":"42","author":"Ford","year":"1990","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0245","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1073\/pnas.91.9.3497","article-title":"Cell biological mechanisms of multidrug resistance in tumors","volume":"91","author":"Simon","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0250","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1248\/bpb.24.612","article-title":"Reversal of vinblastine resistance in human leukemic cells by haloperidol and dihydrohaloperidol","volume":"24","author":"Kataoka","year":"2001","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0255","first-page":"CD003545","article-title":"Trifluoperazine for schizophrenia","author":"Marques","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0260","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.201207-1180OC","article-title":"Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer","volume":"186","author":"Yeh","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0265","article-title":"Cancer cells stemness: a doorstep to targeted therapy","author":"Prasad","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"10","key":"10.1016\/j.semcancer.2020.03.011_bib0270","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41419-018-1046-3","article-title":"The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0\/G1 arrest and apoptosis","volume":"9","author":"Feng","year":"2018","journal-title":"Cell Death Dis."},{"issue":"5789","key":"10.1016\/j.semcancer.2020.03.011_bib0275","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/bmj.4.5789.710","article-title":"Controlled trial of penfluridol in acute psychosis","volume":"4","author":"van Praag","year":"1971","journal-title":"Br. Med. J."},{"issue":"5A","key":"10.1016\/j.semcancer.2020.03.011_bib0280","first-page":"1711","article-title":"Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin","volume":"14","author":"Hait","year":"1994","journal-title":"Anticancer Res."},{"issue":"20","key":"10.1016\/j.semcancer.2020.03.011_bib0285","doi-asserted-by":"crossref","first-page":"32960","DOI":"10.18632\/oncotarget.16515","article-title":"Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1","volume":"8","author":"Ranjan","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0290","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317705517","article-title":"Penfluridol induces endoplasmic reticulum stress leading to autophagy in pancreatic cancer","volume":"39","author":"Ranjan","year":"2017","journal-title":"Tumour Biol."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0295","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/0008-5472.CAN-15-1233","article-title":"Penfluridol: an antipsychotic agent suppresses metastatic tumor growth in triple-negative breast Cancer by inhibiting integrin signaling Axis","volume":"76","author":"Ranjan","year":"2016","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113466","article-title":"The roles of autophagy in Cancer","volume":"19","author":"Yun","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0305","doi-asserted-by":"crossref","first-page":"26165","DOI":"10.1038\/srep26165","article-title":"Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis","volume":"6","author":"Ranjan","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0310","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41598-019-41632-0","article-title":"Penfluridol overcomes paclitaxel resistance in metastatic breast cancer","volume":"9","author":"Gupta","year":"2019","journal-title":"Sci. Rep."},{"issue":"47","key":"10.1016\/j.semcancer.2020.03.011_bib0315","doi-asserted-by":"crossref","first-page":"29371","DOI":"10.1016\/S0021-9258(18)43886-0","article-title":"Cholesterol homeostasis. Modulation by amphiphiles","volume":"269","author":"Lange","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0320","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bbrc.2004.01.066","article-title":"Chronic exposure to U18666A induces apoptosis in cultured murine cortical neurons","volume":"315","author":"Cheung","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0325","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2006.08.019","article-title":"Effects of chlorpromazine on plasma membrane permeability and fluidity in the rat brain: a dynamic positron autoradiography and fluorescence polarization study","volume":"31","author":"Maruoka","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1-3","key":"10.1016\/j.semcancer.2020.03.011_bib0330","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bpc.2008.02.014","article-title":"Human cells and cell membrane molecular models are affected in vitro by chlorpromazine","volume":"135","author":"Suwalsky","year":"2008","journal-title":"Biophys. Chem."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0335","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7314\/APJCP.2014.15.1.489","article-title":"Anti-tumor effects of penfluridol through dysregulation of cholesterol homeostasis","volume":"15","author":"Wu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"29","key":"10.1016\/j.semcancer.2020.03.011_bib0340","doi-asserted-by":"crossref","first-page":"47632","DOI":"10.18632\/oncotarget.17425","article-title":"Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth","volume":"8","author":"Ranjan","year":"2017","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.semcancer.2020.03.011_bib0345","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1073\/pnas.80.16.5122","article-title":"Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists","volume":"80","author":"Gould","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0350","first-page":"421","article-title":"Pimozide: use in Tourette\u2019s syndrome","volume":"19","author":"Colvin","year":"1985","journal-title":"Drug Intell. Clin. Pharm."},{"issue":"1 Pt 2","key":"10.1016\/j.semcancer.2020.03.011_bib0355","first-page":"I12","article-title":"Patterns of dyslipoproteinemia in selected north american populations. The lipid research clinics program prevalence study","volume":"73","author":"LaRosa","year":"1986","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0360","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1310\/hpj4902-134","article-title":"Pimozide: parasitosis (delusional)","volume":"49","author":"Generali","year":"2014","journal-title":"Hosp. Pharm."},{"issue":"8116","key":"10.1016\/j.semcancer.2020.03.011_bib0365","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(79)91025-0","article-title":"Treatment of metastatic malignant melanoma with pimozide","volume":"1","author":"Taub","year":"1979","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0370","first-page":"155","article-title":"Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients","volume":"67","author":"Neifeld","year":"1983","journal-title":"Cancer Treat. Rep."},{"issue":"17","key":"10.1016\/j.semcancer.2020.03.011_bib0375","first-page":"5399","article-title":"Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine","volume":"50","author":"Strobl","year":"1990","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib0380","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0385","first-page":"1129","article-title":"Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges","volume":"12","author":"Hoshida","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0390","doi-asserted-by":"crossref","first-page":"17593","DOI":"10.18632\/oncotarget.4307","article-title":"The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0395","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2017.01.029","article-title":"Potential therapeutic targets of epithelial-mesenchymal transition in melanoma","volume":"391","author":"Pearlman","year":"2017","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.011_bib0400","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0049","article-title":"PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0405","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.lfs.2018.08.027","article-title":"Pimozide suppresses colorectal cancer via inhibition of Wnt\/beta-catenin signaling pathway","volume":"209","author":"Ren","year":"2018","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0410","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ijc.24813","article-title":"Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target","volume":"126","author":"Wiklund","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.011_bib0415","doi-asserted-by":"crossref","first-page":"e0132072","DOI":"10.1371\/journal.pone.0132072","article-title":"In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0420","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10822-014-9811-6","article-title":"Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study","volume":"29","author":"Patil","year":"2015","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0425","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.27889","article-title":"Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load","volume":"62","author":"Sinn","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0430","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025569","article-title":"Malaria pathogenesis","volume":"8","author":"Milner","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0435","series-title":"Economics of Malaria Drugs in an Age of Resistance","article-title":"In saving lives, buying time","year":"2004"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0440","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0445","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/gm326","article-title":"Drug repositioning for personalized medicine","volume":"4","author":"Li","year":"2012","journal-title":"Genome Med."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0450","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/oxfordjournals.aje.a115189","article-title":"Effect of a malaria suppression program on the incidence of African Burkitt\u2019s lymphoma","volume":"129","author":"Geser","year":"1989","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0455","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jac\/dkv018","article-title":"Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases","volume":"70","author":"Al-Bari","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0460","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3171\/foc.2003.14.2.4","article-title":"Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine","volume":"14","author":"Briceno","year":"2003","journal-title":"Neurosurg. Focus"},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0465","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-144-5-200603070-00008","article-title":"Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial","volume":"144","author":"Sotelo","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0470","doi-asserted-by":"crossref","first-page":"e014961","DOI":"10.1136\/bmjopen-2016-014961","article-title":"Study protocol of a phase IB\/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours","volume":"7","author":"Molenaar","year":"2017","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0475","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198708273170905","article-title":"Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum","volume":"317","author":"Krogstad","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0480","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/0008-5472.CAN-12-2464","article-title":"Chloroquine in cancer therapy: a double-edged sword of autophagy","volume":"73","author":"Kimura","year":"2013","journal-title":"Cancer Res."},{"issue":"38","key":"10.1016\/j.semcancer.2020.03.011_bib0485","doi-asserted-by":"crossref","first-page":"e1802337","DOI":"10.1002\/smll.201802337","article-title":"Photosensitizer and Autophagy Promoter Coloaded ROS-Responsive Dendrimer-Assembled Carrier for Synergistic Enhancement of Tumor Growth Suppression","volume":"14","author":"Wang","year":"2018","journal-title":"Small"},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib0490","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI20039","article-title":"Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene","volume":"112","author":"Qu","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.semcancer.2020.03.011_bib0495","doi-asserted-by":"crossref","first-page":"e47357","DOI":"10.1371\/journal.pone.0047357","article-title":"Chloroquine or chloroquine-PI3K\/Akt pathway inhibitor combinations strongly promote gamma-irradiation-induced cell death in primary stem-like glioma cells","volume":"7","author":"Firat","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0500","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.radonc.2013.06.033","article-title":"EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival","volume":"108","author":"Jutten","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"27","key":"10.1016\/j.semcancer.2020.03.011_bib0505","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1038\/s41388-019-0802-x","article-title":"The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to gamma-secretase inhibition","volume":"38","author":"Hounjet","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0510","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbi.2017.11.009","article-title":"Chloroquine upregulates TRAIL\/TRAILR2 expression and potentiates doxorubicin anti-tumor activity in thioacetamide-induced hepatocellular carcinoma model","volume":"279","author":"Helmy","year":"2018","journal-title":"Chem. Biol. Interact."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0515","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.celrep.2016.12.051","article-title":"Chloroquine-inducible Par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasis","volume":"18","author":"Burikhanov","year":"2017","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0520","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1081\/IPH-200067736","article-title":"Chemoprevention by pyrimethamine","volume":"27","author":"Saadat","year":"2005","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0525","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13046-016-0409-9","article-title":"New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study","volume":"35","author":"Tommasino","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0530","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2174\/1568009616666160617103301","article-title":"Pyrimethamine as a potent and selective inhibitor of acute myeloid leukemia identified by high-throughput drug screening","volume":"16","author":"Sharma","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0535","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood.V99.5.1627","article-title":"Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation","volume":"99","author":"Hevehan","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061787","article-title":"STAT3 interactors as potential therapeutic targets for Cancer treatment","volume":"19","author":"Laudisi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0545","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-017-2057-0","article-title":"The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer","volume":"67","author":"Khan","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib0550","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.4161\/auto.26506","article-title":"The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death","volume":"9","author":"Qiao","year":"2013","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0555","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc.2017.104","article-title":"Ribosome biogenesis in cancer: new players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0560","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrc.2018.3","article-title":"Corrigendum: ribosome biogenesis in cancer: new players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0565","article-title":"The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity","author":"Espinoza","year":"2019","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0570","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dks504","article-title":"Antimalarial pharmacology and therapeutics of atovaquone","volume":"68","author":"Nixon","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.011_bib0575","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0006-2952(92)90213-3","article-title":"Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4\u2019-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)","volume":"43","author":"Fry","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"29","key":"10.1016\/j.semcancer.2020.03.011_bib0580","doi-asserted-by":"crossref","first-page":"27458","DOI":"10.1074\/jbc.M502319200","article-title":"Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system","volume":"280","author":"Mather","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.semcancer.2020.03.011_bib0585","doi-asserted-by":"crossref","first-page":"34084","DOI":"10.18632\/oncotarget.9122","article-title":"Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells","volume":"7","author":"Fiorillo","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0590","first-page":"1697","article-title":"Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma","volume":"8","author":"Gao","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"14","key":"10.1016\/j.semcancer.2020.03.011_bib0595","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","article-title":"Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent","volume":"128","author":"Xiang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0600","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-18-1286","article-title":"Atovaquone: an antiprotozoal drug, suppresses primary and resistant breast tumor growth by inhibiting HER2\/beta-catenin signaling","author":"Gupta","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl 66","key":"10.1016\/j.semcancer.2020.03.011_bib0605","first-page":"33 S66 1","article-title":"History of diabetes insipidus","volume":"33","author":"Valenti","year":"2016","journal-title":"G. Ital. Nefrol."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0610","first-page":"474","article-title":"[Unusual bullous dermatitis due to pine caterpillars]","volume":"33","author":"Moschen","year":"1965","journal-title":"Arch. Ital. Dermatol. Venereol. Sessuol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0615","first-page":"29","article-title":"Management of blood glucose in type 2 diabetes mellitus","volume":"79","author":"Ripsin","year":"2009","journal-title":"Am. Fam. Physician"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0620","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/cbdd.13013","article-title":"New insights into antidiabetic drugs: possible applications in cancer treatment","volume":"90","author":"Shafiei-Irannejad","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"issue":"Pt 3","key":"10.1016\/j.semcancer.2020.03.011_bib0625","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0630","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1593\/tlo.13556","article-title":"Antidiabetic drug metformin prevents progression of pancreatic Cancer by targeting in part Cancer stem cells and mTOR signaling","volume":"6","author":"Mohammed","year":"2013","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0635","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0640","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0645","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"issue":"37","key":"10.1016\/j.semcancer.2020.03.011_bib0650","doi-asserted-by":"crossref","first-page":"32651","DOI":"10.1074\/jbc.M111.238014","article-title":"Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1\/TSC2-Rheb GTPase pathway","volume":"286","author":"Yoshida","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0655","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.semcancer.2020.03.011_bib0660","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1","volume":"71","author":"Ben Sahra","year":"2011","journal-title":"Cancer Res."},{"issue":"Suppl 2","key":"10.1016\/j.semcancer.2020.03.011_bib0665","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/dmrr.249","article-title":"The mode of action of thiazolidinediones","volume":"18","author":"Hauner","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0670","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/cbdd.12737","article-title":"Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: therapeutic strategies","volume":"88","author":"Yousefi","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.011_bib0675","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(04)01509-8","article-title":"Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists","volume":"5","author":"Grommes","year":"2004","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0680","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1006\/bbrc.2001.5491","article-title":"Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators","volume":"286","author":"Yin","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0685","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/gast.2003.50067","article-title":"Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice","volume":"124","author":"Osawa","year":"2003","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.semcancer.2020.03.011_bib0690","first-page":"3344","article-title":"Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo","volume":"58","author":"Kubota","year":"1998","journal-title":"Cancer Res."},{"issue":"1-2","key":"10.1016\/j.semcancer.2020.03.011_bib0695","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-5793(99)00871-6","article-title":"Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells","volume":"455","author":"Takahashi","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0700","first-page":"79","article-title":"Troglitazone reverses the multiple drug resistance phenotype in cancer cells","volume":"3","author":"Davies","year":"2009","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0705","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.canlet.2009.07.011","article-title":"Troglitazone inhibits histone deacetylase activity in breast cancer cells","volume":"288","author":"Davies","year":"2010","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0710","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1745-7254.2005.00753.x","article-title":"Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines","volume":"26","author":"Yang","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"issue":"10","key":"10.1016\/j.semcancer.2020.03.011_bib0715","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus","volume":"86","author":"Razonable","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"23","key":"10.1016\/j.semcancer.2020.03.011_bib0720","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1002\/cncr.25530","article-title":"Cancer incidence in the multicenter AIDS cohort study before and during the HAART era","volume":"116","author":"Seaberg","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0725","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.21873\/anticanres.12620","article-title":"Delanzomib interacts with ritonavir synergistically to cause endoplasmic reticulum stress in renal Cancer cells","volume":"38","author":"Isono","year":"2018","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0730","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/ph7010046","article-title":"Ritonavir-mediated induction of apoptosis in pancreatic Cancer Occurs via the RB\/E2F-1 and AKT pathways","volume":"7","author":"Batchu","year":"2014","journal-title":"Pharmaceuticals Basel (Basel)"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0735","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-05-1167","article-title":"Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer","volume":"12","author":"Srirangam","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0740","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-8-26","article-title":"Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells","volume":"8","author":"Kumar","year":"2009","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0745","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3727\/096504017X14957929842972","article-title":"Nelfinavir and ritonavir kill bladder Cancer cells synergistically by inducing endoplasmic reticulum stress","volume":"26","author":"Sato","year":"2018","journal-title":"Oncol. Res."},{"issue":"20","key":"10.1016\/j.semcancer.2020.03.011_bib0750","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1158\/0008-5472.CAN-03-2677","article-title":"HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo","volume":"64","author":"Ikezoe","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0755","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.29812","article-title":"Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model","volume":"138","author":"Hendrikx","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0760","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3727\/096504016X14666990347635","article-title":"Ritonavir interacts with belinostat to cause endoplasmic reticulum stress and histone acetylation in renal Cancer cells","volume":"24","author":"Isono","year":"2016","journal-title":"Oncol. Res."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0765","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3892\/mco.2014.349","article-title":"Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth","volume":"2","author":"Sato","year":"2014","journal-title":"Mol. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2011.11.033","article-title":"Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells","volume":"79","author":"Sato","year":"2012","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2010.04.042","article-title":"Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells","volume":"76","author":"Sato","year":"2010","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0780","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1128\/AAC.44.6.1686-1690.2000","article-title":"Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults","volume":"44","author":"McDowell","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib0785","doi-asserted-by":"crossref","first-page":"e14221","DOI":"10.1371\/journal.pone.0014221","article-title":"The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines","volume":"5","author":"Carlini","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0790","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3892\/or.2016.4819","article-title":"Zidovudine, abacavir and lamivudine increase the radiosensitivity of human esophageal squamous cancer cell lines","volume":"36","author":"Chen","year":"2016","journal-title":"Oncol. Rep."},{"issue":"2A","key":"10.1016\/j.semcancer.2020.03.011_bib0795","first-page":"713","article-title":"Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy","volume":"18","author":"Tong","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0800","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lfs.2018.11.002","article-title":"Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity","volume":"215","author":"Benedetti","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0805","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2019.02.050","article-title":"Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction","volume":"451","author":"Yang","year":"2019","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0810","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/ijmm.2015.2289","article-title":"Amantadine inhibits cellular proliferation and induces the apoptosis of hepatocellular cancer cells in vitro","volume":"36","author":"Lan","year":"2015","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0815","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3892\/ijo.2017.3860","article-title":"Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer","volume":"50","author":"Jiang","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"11-12","key":"10.1016\/j.semcancer.2020.03.011_bib0820","first-page":"519","article-title":"Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice","volume":"18","author":"Yang","year":"2010","journal-title":"Oncol. Res."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0825","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0830","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CAD.0b013e3283612a71","article-title":"The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines\u2019 in-vitro and in-vivo xenografts","volume":"24","author":"Deberne","year":"2013","journal-title":"Anticancer Drugs"},{"issue":"18","key":"10.1016\/j.semcancer.2020.03.011_bib0835","doi-asserted-by":"crossref","first-page":"25549","DOI":"10.18632\/oncotarget.8224","article-title":"Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients","volume":"7","author":"Deutsch","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.semcancer.2020.03.011_bib0840","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/QAD.0b013e3283625444","article-title":"Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system","volume":"27","author":"Hecht","year":"2013","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0845","first-page":"1728","article-title":"Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation","volume":"15","author":"Hecht","year":"2018","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib0850","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2014-0345","article-title":"A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer","volume":"19","author":"Houede","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0855","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-004-0725-1","article-title":"Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients","volume":"88","author":"Yeo","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0860","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1593\/tlo.13499","article-title":"CCR5 antagonism by Maraviroc reduces the potential for gastric Cancer cell dissemination","volume":"6","author":"Mencarelli","year":"2013","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.011_bib0865","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12032-015-0607-x","article-title":"CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells","volume":"32","author":"Pervaiz","year":"2015","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0870","first-page":"93","article-title":"CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer","volume":"42","author":"Pervaiz","year":"2019","journal-title":"Cell. Oncol. Dordr. (Dordr)"},{"issue":"14","key":"10.1016\/j.semcancer.2020.03.011_bib0875","first-page":"3772","article-title":"ICI D1694 and idoxuridine: a synergistic antitumor combination","volume":"54","author":"Pressacco","year":"1994","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib0880","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/auto.5224","article-title":"Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy","volume":"4","author":"Gills","year":"2008","journal-title":"Autophagy"},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0885","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/cbt.8.3.7339","article-title":"Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis","volume":"8","author":"Bruning","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0890","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbrc.2008.10.167","article-title":"Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells","volume":"377","author":"Bruning","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0895","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-9-19","article-title":"The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization","volume":"9","author":"Bruning","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0900","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2019.01.045","article-title":"Metformin combined with nelfinavir induces SIRT3\/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice","volume":"848","author":"Xia","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"16","key":"10.1016\/j.semcancer.2020.03.011_bib0905","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2007.15.2355","article-title":"Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer","volume":"26","author":"Brunner","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0910","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","article-title":"ARCII: a phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer","volume":"119","author":"Wilson","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0915","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ygyno.2008.08.006","article-title":"Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells","volume":"111","author":"Stefanidis","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.011_bib0920","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/pros.20923","article-title":"Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo","volume":"69","author":"Landriscina","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.semcancer.2020.03.011_bib0925","first-page":"117","article-title":"Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu(R)) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance","volume":"7","author":"O\u2019Shea","year":"2014","journal-title":"Onco. Ther."},{"issue":"10","key":"10.1016\/j.semcancer.2020.03.011_bib0930","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3109\/10428194.2010.496506","article-title":"Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?","volume":"51","author":"Borden","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.011_bib0935","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-10-2334","article-title":"Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer","volume":"17","author":"Pettersson","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0940","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.amjms.2017.03.025","article-title":"Antiviral drug ribavirin targets thyroid Cancer cells by inhibiting the eIF4E-beta-Catenin Axis","volume":"354","author":"Shen","year":"2017","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0945","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1868-7083-3-8","article-title":"Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines","volume":"3","author":"Sappok","year":"2011","journal-title":"Clin. Epigenetics"},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0950","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2019.01.117","article-title":"Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer","volume":"510","author":"Jin","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.011_bib0955","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.carres.2009.05.017","article-title":"Synthesis of novel ribavirin hydrazone derivatives and anti-proliferative activity against A549 lung cancer cells","volume":"344","author":"Liu","year":"2009","journal-title":"Carbohydr. Res."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0960","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JTO.0b013e31820c9e3c","article-title":"The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin","volume":"6","author":"Srirangam","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib0965","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/cas.13242","article-title":"Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation","volume":"108","author":"Sato","year":"2017","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0970","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3892\/ol.2016.5008","article-title":"The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines","volume":"12","author":"Bandiera","year":"2016","journal-title":"Oncol. Lett."},{"issue":"18","key":"10.1016\/j.semcancer.2020.03.011_bib0975","first-page":"5230","article-title":"The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells","volume":"62","author":"Pajonk","year":"2002","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib0980","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ygyno.2008.11.028","article-title":"The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells","volume":"112","author":"McLean","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2020.03.011_bib0985","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/1756-0500-6-445","article-title":"Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein","volume":"6","author":"Fujita","year":"2013","journal-title":"BMC Res. Notes"},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.011_bib0990","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10637-011-9704-7","article-title":"The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells","volume":"30","author":"Bruning","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib0995","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.eururo.2009.02.025","article-title":"Reduction of serum prostate-specific antigen levels following varicella-zoster infection and valaciclovir treatment in prostate cancer","volume":"56","author":"Jurhill","year":"2009","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.011_bib1000","first-page":"2341","article-title":"Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors","volume":"57","author":"Wagner","year":"1997","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib1005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.freeradbiomed.2008.10.023","article-title":"Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism","volume":"46","author":"Mattson","year":"2009","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.011_bib1010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1023\/A:1008249803523","volume":"8","author":"Falcone","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2020.03.011_bib1015","doi-asserted-by":"crossref","first-page":"e1795","DOI":"10.1038\/cddis.2015.172","article-title":"Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3beta-Snail pathway","volume":"6","author":"Namba","year":"2015","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.011_bib1020","first-page":"579","article-title":"Phase i\/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-cancer, renal-cell carcinoma and malignant-melanoma","volume":"6","author":"Sharfman","year":"1995","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib1025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3892\/ol.2016.4074","article-title":"Repurposing antipsychotics as glioblastoma therapeutics: potentials and challenges","volume":"11","author":"Lee","year":"2016","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.011_bib1030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14740338.2016.1175428","article-title":"Adverse neuropsychiatric effects of antimalarial drugs","volume":"15","author":"Grabias","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.semcancer.2020.03.011_bib1035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2017.00006","article-title":"Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management","volume":"8","author":"Chaudhury","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib1040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.011_bib1045","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","article-title":"Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer","volume":"1871","author":"Nowak-Sliwinska","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.011_bib1050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40360-017-0128-7","article-title":"Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects","volume":"18","author":"Chartier","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"10","key":"10.1016\/j.semcancer.2020.03.011_bib1055","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.semcancer.2020.03.011_bib1060","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3389\/fphar.2017.00927","article-title":"Drug repositioning in the mirror of patenting: surveying and mining uncharted territory","volume":"8","author":"Mucke","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20300778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20300778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:43:05Z","timestamp":1760917385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X20300778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":212,"alternative-id":["S1044579X20300778"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.011","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug rechanneling: A novel paradigm for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}